http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1377591-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d70b6cd33734e8b594ea10e154909b10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-53 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402 |
| filingDate | 2002-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00395f3d7d4e0909fb93aaef60a1f1fd |
| publicationDate | 2006-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1377591-B1 |
| titleOfInvention | Tumour inhibiting gallium compounds |
| abstract | The invention relates to a compound of the general formula (I) where R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB>, R<SUB>1</SUB>', R<SUB>2</SUB>', R<SUB>3</SUB>' and R<SUB>4</SUB>' are independently of one another hydrogen, C<SUB>1</SUB>-C<SUB>15</SUB>-alkyl, C<SUB>2</SUB>-C<SUB>15</SUB>-alkenyl, C<SUB>2</SUB>-C<SUB>15</SUB>-alkinyl, C<SUB>3</SUB>-C<SUB>16</SUB>-cycloalkyl, C<SUB>3</SUB>-C<SUB>16</SUB>-cycloalkenyl, aryl or a heterocyclus which in each case can be substituted or unsubstituted, Y is a physiologically compatible anion, and n is 1 or 2, as well as its application to the prophylaxis and/or tretment of cancer illnesses. |
| priorityDate | 2001-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.